Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/38738
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPage-Sharp M.en
dc.contributor.authorSalman S.en
dc.contributor.authorBenn K.en
dc.contributor.authorButtery J.P.en
dc.contributor.authorDavis T.M.E.en
dc.date.accessioned2021-05-14T13:13:32Zen
dc.date.available2021-05-14T13:13:32Zen
dc.date.copyright2017en
dc.date.created20170922en
dc.date.issued2017-09-22en
dc.identifier.citationAmerican Journal of Case Reports. 18 (pp 883-886), 2017. Date of Publication: 11 Aug 2017.en
dc.identifier.issn1941-5923 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/38738en
dc.description.abstractObjective: Unusual or unexpected effect of treatment Background: Azithromycin is a macrolide antibiotic widely used to treat respiratory, urogenital, and other infections. Gastrointestinal upset, headache, and dizziness are common adverse effects, and prolongation of the rate-corrected electrocardiographic QT interval and malignant arrhythmias have been reported. There are rare reports of bradycardia and hypothermia but not in the same patient. Case Report: A 4-year-old boy given intravenous azithromycin as part of treatment for febrile neutropenia complicating leukemia chemotherapy developed hypothermia (rectal temperature 35.2degreeC) and bradycardia (65 beats/minute) after the second dose, which resolved over several days post-treatment, consistent with persistence of high tissue azithromycin concentrations relative to those in plasma. A sigmoid Emax pharmacokinetic/pharmacodynamic model suggested a maximal azithromycin-associated reduction in heart rate of 23 beats/minute. Monitoring for these potential adverse effects should facilitate appropriate supportive care in similar cases. Conclusion(s): Recommended azithromycin doses can cause at least moderate bradycardia and hypothermia in vulnerable pediatric patients, adverse effects that should prompt appropriate monitoring and which may take many days to resolve.Copyright © Am J Case Rep, 2017.en
dc.languageEnglishen
dc.languageenen
dc.publisherInternational Scientific Information, Inc. (E-mail: office@isl-science.com)en
dc.relation.ispartofAmerican Journal of Case Reportsen
dc.titleBradycardia and hypothermia complicating azithromycin treatment.en
dc.typeArticleen
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.12659/AJCR.905400en
dc.publisher.placePolanden
dc.identifier.pubmedid28798290 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28798290]en
dc.identifier.source618282864en
dc.identifier.institution(Benn, Buttery) Department of Infection and Immunity, Monash Children's Hospital, Clayton, VIC, Australia (Salman, Davis) School of Medicine, University of Western Australia, Crawley, WA, Australia (Page-Sharp) School of Pharmacy, Curtin University of Technology, Bentley, WA, Australia (Buttery) Department of Pediatrics, Monash University, Clayton, VIC, Australia (Buttery) Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC, Australiaen
dc.description.addressT.M.E. Davis, School of Medicine, University of Western Australia, Crawley, WA, Australia. E-mail: tim.davis@uwa.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2017 Elsevier B.V., All rights reserved.en
dc.subect.keywordsAzithromycin Bradycardia Hypothermiaen
dc.identifier.authoremailDavis T.M.E.; tim.davis@uwa.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Collections:Articles
Show simple item record

Page view(s)

38
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.